Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Change in Cash (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Change in Cash data on record, last reported at $86.9 million in Q1 2026.

  • On a quarterly basis, Change in Cash rose 311.78% to $86.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$85.9 million, a 67.53% increase, with the full-year FY2025 number at -$213.8 million, down 2184.11% from a year prior.
  • Change in Cash reached $86.9 million in Q1 2026 per PCVX's latest filing, up from -$107.1 million in the prior quarter.
  • Over the last five years, Change in Cash for PCVX hit a ceiling of $556.3 million in Q4 2022 and a floor of -$662.3 million in Q4 2024.
  • A 5-year average of $11.3 million and a median of $14.3 million in 2023 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: plummeted 442.14% in 2023, then soared 3609.86% in 2024.
  • Tracing PCVX's Change in Cash over 5 years: stood at $556.3 million in 2022, then tumbled by 126.55% to -$147.7 million in 2023, then tumbled by 348.47% to -$662.3 million in 2024, then skyrocketed by 83.83% to -$107.1 million in 2025, then surged by 181.11% to $86.9 million in 2026.
  • Business Quant data shows Change in Cash for PCVX at $86.9 million in Q1 2026, -$107.1 million in Q4 2025, and -$25.5 million in Q3 2025.